Compositions and methods for minimizing adverse drug...

Details Compositions and methods for minimizing adverse drug... Compositions and methods for minimizing adverse drug...

2006-08-08

2006-08-08

Ghali, Isis (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Web, sheet or filament bases; compositions of bandages; or...

C424S448000, C424S434000, C424S435000, C424S422000

Reexamination Certificate

active

07087241

ABSTRACT:
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

REFERENCES:
patent: 4652441 (1987-03-01), Okada et al.
patent: 4959217 (1990-09-01), Sanders et al.
patent: 5028430 (1991-07-01), Sanders et al.
patent: 5152997 (1992-10-01), Ebert et al.
patent: 5212199 (1993-05-01), Heiber et al.
patent: 5227169 (1993-07-01), Heiber et al.
patent: 5575987 (1996-11-01), Kamei et al.
patent: 5677346 (1997-10-01), Aberg et al.
patent: 5759583 (1998-06-01), Iwamoto et al.
patent: 5762953 (1998-06-01), Venkateshwaran
patent: 5840754 (1998-11-01), Guittard et al.
patent: 5922342 (1999-07-01), Shah et al.
patent: 5972369 (1999-10-01), Roorda et al.
patent: 5985305 (1999-11-01), Peery et al.
patent: WO 92/10231 (1992-06-01), None
patent: WO 92/20377 (1992-11-01), None
patent: WO 93/23025 (1993-11-01), None
patent: WO 95/09007 (1995-04-01), None
patent: WO 99/48493 (1999-09-01), None
patent: WO 99/48494 (1999-09-01), None
Noronha-Blob, L. and Kachur, J.F., Enantiomers of Oxybutynin: In Vitro Pharmacological Characterization at M1, M2and M3Muscarinic Receptors and in Vivo Effects on Urinary Bladder Contraction, Mydriasis and Salivary Secretion in Guinea Pigs, Journal of Pharmacology and Experimental Therapeutics, vol. 256, pp. 562-567, (1990).
Merritt, Ernest W. and Cooper, Eugene R., Diffusion Apparatus for Skin Penetration, Journal of controlled Release, vol. 1, pp. 161-162, (1984).
Kachur, James F. et al., “R and S Enantiomers of Oxybutynin: Pharmacological Effects in Guinea Pig Bladder and Intestine,” The Journal of Pharmacology and Experimental Therapeutics, vol. 247: 3, pp. 867-872, (1988).
Johnson & Johnson 2Q EPS 89c, Dow Jones News Service, Jul. 19, 2005, pp. 1-2.
Johnson & Johnson Reports 2005 Second-Quarter Sales Increase of 11.1% and EPS of $.89 Versus $.82 a Year Ago; Excluding In-Process Research and Development Charges and Revised Tax Impact of American Jobs Creation Act, EPS Increased 13.4%, PR Newswire, Jul. 19, 2005, pp. 1-7.
Drug Delivery System, Transmucosal Film, Oxybutynin Auxilium, Phase Change I, USA, R& D Focus Drug News, UK, Jul. 18, 2005, p. 1.
Buyse, Gunnar et al., “Intravesical Oxybutynin for Neurogenic Bladder Dysfunction: Less Systemic Side Effects Due to Reduced first Pass Metabolism,” The Journal of Urology, Sep. 1998, pp. 892-896, vol. 160.
Gupta, Suneel K. (PH.D) et al., “Pharmacokinetics of an Oral Once-a-Day Controlled-Release Oxybutynin Formulation Compared with Immediate-Release Oxybutynin,” J. Clin. Pharmacol, 1999, pp. 289-296, vol. 39.

Affiliated with

Also associated with

Rating

Compositions and methods for minimizing adverse drug... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for minimizing adverse drug..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for minimizing adverse drug... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3675139